ARWR Stock News 10.77 05/18/2014 17:40:53 Arrowhead Research

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arrowhead Research Corp (ARWR) 10.77 $ARWR

Earnings Release Results, and Leadership Appointments - Analyst Notes on Halozyme, MannKind, Arrowhead, Idera and BioCryst
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), MannKind Corp. (NASDAQ: MNKD), Arrowhead Research Corp. (NASDAQ: ARWR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2534-100free.

Downtrend Call Working As Arrowhead Research Stock Falls 40.5% (ARWR)
Comtex SmarTrend(R) - Thu May 15, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.54% as of today's recent price of $11.02.

Shares of ARWR Down 45.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 month, Arrowhead Research has returned 45.94% as of today's recent price of $10.02.

Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver

Arrowhead to Present at Upcoming Scientific Conferences
Business Wire - Tue May 06, 3:02PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May.

Arrowhead Reports Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue May 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 second quarter ended March 31, 2014. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations.

Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference
Business Wire - Thu May 01, 6:31AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.D., Chief Operating Officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 12:50 p.m. EDT at the InterContinental hotel in Boston.

Arrowhead to Report Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 second quarter ended March 31, 2014, on Tuesday, May 6, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations.

Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at:

Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00.

35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99.

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 131

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 187

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 122

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 44

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 127

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 44

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading

Top 5 Most Recently Viewed Articles

New Research Grants Support Diet Impact on Health Outcomes

Updated Category News Views 85

New Research Grants Empower Understanding of Diet and Health Healthcare technology company Komodo Health has recently announced the recipients of its 2024 Diet-Related Health (DRH) grants. These grants are aimed at advancing research that explores the pivotal influence of diet on various health outcomes. Funded by the Robert Wood Johnson Foundation (RWJF), the DRH program...

Continue Reading
Innovative Cardiology Care with Dr. Butkevich's Hybrid Choice™

Updated Category News Views 118

Dr. Alexander Butkevich Introduces Hybrid Choice™ Concierge Program Patients in the Houston area can now access a unique cardiology service from Dr. Alexander Butkevich, MD, thanks to Concierge Choice Physicians. This innovative program provides enhanced connectivity and personalized care adjustments, catering to the evolving needs of patients. The Unique Benefits of...

Continue Reading
Revolutionizing Cryptocurrency with ALR MINER's AI Cloud Service

Updated Category News Views 274

Revolutionizing Cryptocurrency Mining ALR MINER has emerged as a pioneering force in the cryptocurrency world by launching a groundbreaking zero-cost AI cloud mining platform. This innovative approach gives users the opportunity to earn cryptocurrencies like Bitcoin, Ethereum, Dogecoin, and Ripple without any upfront costs, reshaping the way mining is perceived and...

Continue Reading
Instacart Positioned Well Amid Competition with Major Rivals

Updated Category News Views 279

Instacart's Competitive Landscape Instacart (NASDAQ:CART) has made a notable mark in the online grocery delivery sector, and analysts from Goldman Sachs believe its stock is already reflecting the ongoing competition. Despite challenges from giants like Amazon, Uber, and DoorDash, there are reasons to maintain a bullish outlook on Instacart. Supporting Recommendation from...

Continue Reading
Daily Mango Benefits: Heart Health Insights for Women

Updated Category News Views 238

Exploring Mango's Heart Health Benefits Mangos have long been celebrated for their vibrant flavor and nutritional perks. Recent studies now emerge, shedding light on the potential heart and metabolic health benefits of daily mango consumption, particularly for postmenopausal women. This demographic faces unique challenges as they navigate changes in their bodies and...

Continue Reading